Related Experiment Video
Updated: Apr 7, 2026

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.8K
Nurses' role in platelet transfusion clinical trials
Summary
Research nurses are vital for clinical trials coordinated by the NHS Blood and Transplant Clinical Trials Unit (CTU). Their feedback improves trial design and management, ensuring effective patient care during studies like platelet transfusions.
Area of Science:
- Clinical research nursing
- Hematology clinical trials
- Healthcare management
Background:
- The NHS Blood and Transplant Clinical Trials Unit (CTU) coordinates numerous studies.
- Effective coordination relies on strong communication between central units and participating sites.
- Research nurses play a key role in the practical execution of clinical trials.
Purpose of the Study:
- To highlight the essential contributions of research nurses in CTU-coordinated studies.
- To illustrate the collaborative relationship between the CTU and research nurses.
- To demonstrate how research nurse input influences trial processes.
Main Methods:
- Describing the structure and support mechanisms of the CTU for research nurses.
- Using two recent platelet transfusion trials (adult and neonatal) as case examples.
- Detailing the ongoing education, training, and communication strategies employed.
Main Results:
- CTU trial managers, often nurses, foster positive relationships with hospital-based research nurses.
- Continuous education and cooperative working enhance nurse performance and collaboration.
- Regular feedback from research nurses directly informs and refines trial design and management.
Conclusions:
- Research nurses are indispensable to the successful operation of CTU clinical trials.
- A supportive and collaborative environment empowers research nurses to provide valuable insights.
- The integration of research nurse feedback is crucial for optimizing clinical trial conduct and outcomes.
More Related Videos
Related Concept Videos
Formation of the Platelet Plug
10.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.8K
Venous Thrombosis IV: Nursing Management
388
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
388
Structure and Function of Platelets
5.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
5.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

